人民财讯8月4日电，侨源股份（301286）8月4日晚间公告，公司近日与成都新材料产业功能区管委会 (以下简称"成都管委会")签订《投资合作协议》，协议约定公司拟在成都新材料产业化工园区投资电子 级医用级特种气体生产基地，项目计划总投资3.02亿元，其中一期项目投资约1.52亿元；二期项目投资 约1.5亿元。侨源股份同日公告，终止德阳宏晨化工有限责任公司股权收购意向协议。 ...

Core Viewpoint - The company has signed an investment cooperation agreement to establish a special gas production base in Chengdu, with a total planned investment of 302 million yuan, aimed at enhancing its capabilities in the medical and electronic specialty gas sectors [1]. Investment Details - The total planned investment for the project is 302 million yuan, with phase one investment approximately 152 million yuan and phase two investment around 150 million yuan [1]. - Phase one will cover about 38 acres and will include the construction of facilities for producing 20,000 tons/year of electronic-grade carbon dioxide, 20,000 tons/year of medical-grade carbon dioxide, 40,000 tons of industrial-grade carbon dioxide, and a hydrogen recovery and purification unit with a capacity of 1,000 Nm³/h [1]. - Phase two will focus on building production lines for electronic-grade medical carbon dioxide, electronic-grade ultra-pure ammonia, and storage facilities for high-end electronic chemicals and specialty gases [1]. Market Demand and Strategic Expansion - The phase one project is expected to add 20,000 tons/year of high-purity medical-grade carbon dioxide capacity, significantly enhancing the supply of sterile gases to meet the growing demand in biopharmaceuticals and high-end medical devices [1]. - By establishing production capabilities for electronic-grade carbon dioxide and a hydrogen recovery unit, along with the planned electronic-grade ultra-pure ammonia production line, the company aims to penetrate strategic emerging fields such as semiconductor manufacturing and new display technologies, thereby extending its reach from medical gases to higher value-added electronic specialty gases [1].

Core Viewpoint - The company, Qiaoyuan Co., Ltd. (301286.SZ), has signed an investment cooperation agreement with the Chengdu New Materials Industry Functional Zone Management Committee to establish a special gas production base for electronic and medical use in Chengdu, with a total planned investment of 302 million yuan [1]. Group 1: Project Investment Details - The total planned investment for the project is 302 million yuan, with the first phase requiring approximately 152 million yuan and the second phase about 150 million yuan [1]. - The first phase will cover an area of approximately 38 acres and will establish a production capacity of 20,000 tons/year for electronic-grade carbon dioxide, 20,000 tons/year for medical-grade carbon dioxide, 40,000 tons/year for industrial-grade carbon dioxide, and a hydrogen recovery and purification facility with a capacity of 1,000 Nm³/h [1]. Group 2: Strategic Importance - The first phase of the project will add 20,000 tons/year of high-purity medical-grade carbon dioxide capacity, significantly enhancing the supply of sterile gases to meet the increasing demand in biopharmaceuticals and high-end medical devices [1]. - By establishing a production line for 20,000 tons/year of electronic-grade carbon dioxide and a hydrogen recovery and purification facility, along with the planned electronic-grade ultra-pure ammonia production line in the second phase, the company aims to enter strategic emerging fields such as semiconductor manufacturing and new display technologies, extending its reach from medical gases to higher value-added electronic specialty gases [1].

四川侨源气体股份有限公司（以下简称"公司"）第五届董事会第十六 次会议通知于 2025 年 8 月 1 日以通讯方式送达全体董事，本次会议于 2025 年 8 月 4 日以通讯方式召开。本次会议应出席董事 6 名，实际出席 董事 6 名。会议由董事长乔志涌先生召集并主持。本次会议的召开符合《公 司法》和《公司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 1、审议通过《关于拟签署电子级医用级特种气体生产基地投资合作 协议暨对外投资的议案》 经审议，董事会同意公司与成都新材料产业功能区管委会签订《投资 合作协议》，并拟在成都新材料产业化工园区投资电子级医用级特种气体 生产基地项目，项目计划总投资 3.02 亿元，建设电子级医用级特种气体生 产基地项目，项目分两期实施：一期项目投资约 1.52 亿元，用地约 38 亩， 新建 2 万吨/年电子级二氧化碳、2 万吨/年医用级二氧化碳、4 万吨工业级 二氧化碳和 1000Nm³/h 氢气回收提纯装置以及相关配套设施；二期项目投 资约 1.5 亿元，新建电子级医用级二氧化碳生产线、电子级超纯氨生产线、 高端电子化学品和特气的储存经营设施以及相关配套设施。同 ...

证券代码：301286 证券简称：侨源股份 公告编号：2025-045 四川侨源气体股份有限公司 关于终止德阳宏晨化工有限责任公司股权收购 意向协议的公告 公司于 2025 年 1 月 22 日召开的第五届董事会第十二次会议审议通过，就公 司拟通过现金方式间接收购宏晨化工控股权事项，公司与成都兴久兴商贸有限责 任公司（持有宏晨化工 70%股权）之股东苏世军、成都浩煜诚商贸有限公司（持 有宏晨化工 30%股权）之股东张淦和应岚达成初步意向，并于同日共同签署了 《股权收购意向协议》（以下简称"《意向协议》"）。具体内容详见公司于 2025 年 1 月 23 日在巨潮资讯网披露的《关于签署股权收购意向协议的公告》（公告 编号：2025-005）。 二、终止本次股权收购意向事项说明 自本《意向协议》签署以来，公司与其他交易各方就本次股权收购相关事项 进行了积极的沟通磋商，并积极组织交易对方及公司聘请的中介机构开展对宏晨 化工的尽职调查工作。 根据《意向协议》约定："本协议自下列情形之一发生时终止：(1)经双方 协商一致终止；......"，截至本公告披露日，本次交易各方未能就本次收购事项 达成最终共识，为维护公司及全 ...

证券代码：301286 证券简称：侨源股份 公告编号：2025-044 四川侨源气体股份有限公司 关于拟签署电子级医用级特种气体生产基地投资合作协议 暨对外投资的公告 2、法定地址：成都彭州市金彭东路 81 号 3、单位性质：彭州市人民政府的派出机构 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、 对外投资概述 四川侨源气体股份有限公司（以下简称"公司"或"乙方"）近日与成都新材料 产业功能区管委会（以下简称"成都管委会"或"甲方"）签订《投资合作协议》， 协议约定公司拟在成都新材料产业化工园区投资电子级医用级特种气体生产基地（最 终项目名称以乙方或项目公司在行政主管部门立项备案并审批通过为准），项目计划 总投资 3.02 亿元，其中一期项目投资约 1.52 亿元；二期项目投资约 1.5 亿元（具体实 施另行协商）。 2025 年 8 月 4 日，公司召开第五届董事会第十六次会议，审议通过了《关于拟签 署电子级医用级特种气体生产基地投资合作协议暨对外投资的议案》。 本次投资不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的 重大资产重组。根 ...

名称：成都晨源物流有限公司 统一社会信用代码：91510181562011596H 类型：有限责任公司（自然人投资或控股的法人独资） 法定代表人：周见明 注册资本：陆拾玖万元整 成立日期：2010 年 9 月 1 日 住所：四川省成都市都江堰市灌温路 1399 号 证券代码：301286 证券简称：侨源股份 公告编号：2025-042 四川侨源气体股份有限公司 关于全资子公司增加经营范围并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 四川侨源气体股份有限公司之全资子公司成都晨源物流有限公司因业务发 展需要，于近日增加了经营范围，并已完成工商变更登记手续，取得了都江堰市 行政审批局换发的《营业执照》。 一、变更后营业执照的具体情况 经营范围：许可项目：道路危险货物运输。（依法须经批准的项目，经相关 部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为 准）一般项目：特种设备出租；机动车修理和维护；运输设备租赁服务；汽车零 配件零售。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 二、备查文件 成都晨源物流 ...

卫星化学：上半年净利润预增31.32%-53.20% 7月15日晚，卫星化学（002648）发布2025年半年度业绩预告，公司预计上半年实现归属于上市公司股 东的净利润27亿元至31.5亿元，同比增长31.32%-53.20%；预计实现扣除非经常性损益后的净利润28.52 亿元至33.02亿元，同比增长27.65%-47.79%。 资料显示，卫星化学成立于2005年8月，主营业务是(聚)丙烯、丙烯酸及酯、乙二醇、环氧乙烷、环氧 丙烷和聚乙烯等产品的生产和销售。 所属行业：基础化工–化学原料–其他化学原料 中国核建：累计新签合同871.49亿元 7月15日晚，中国核建（601611）发布公告称，截至2025年6月，公司累计实现新签合同871.49亿元，累 计实现营业收入531.84亿元。 资料显示，中国核建成立于2010年12月，主营业务是核电工程建设及工业与民用工程建设。 所属行业：建筑装饰–基础建设–基建市政工程 资料显示，怡球资源成立于2001年3月，主营业务是利用所回收的各种废旧铝资源，进行分选、加工、 熔炼等工序，生产出再生铝合金产品。 所属行业：有色金属–工业金属–铝 光库科技：上半年净利润预增60 ...

Performance Forecast Overview Outlines the company's H1 2025 financial performance forecast, detailing key indicators and expected growth [Performance Forecast Period](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast_1.%20Performance%20Forecast%20Period) Covers Sichuan Qiaoyuan Gas Co., Ltd.'s H1 2025 financial performance, from January 1 to June 30 - The performance forecast period is from **January 1, 2025, to June 30, 2025**[3](index=3&type=chunk) [Key Financial Indicator Forecast](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast_2.%20Performance%20Forecast%20Situation) Company projects H1 2025 net profit growth to **CNY 100-120 million**, a **34.38-61.26%** increase Key Financial Indicators Forecast for H1 2025 | Project | Estimated Profit for Current Period (CNY millions) | Profit for Same Period Last Year (CNY millions) | Year-on-Year Growth Rate (%) | | :------------------------------------ | :--------------------------------------- | :------------------------------------ | :--------------------------- | | Net Profit Attributable to Shareholders of Listed Company | 100.00 — 120.00 | 74.41 | 34.38 — 61.26 | | Net Profit Excluding Non-recurring Gains and Losses | 91.30 — 111.30 | 68.88 | 32.55 — 61.58 | - The company anticipates a **year-on-year increase** in H1 2025 performance[3](index=3&type=chunk) Reasons for Performance Change Details primary drivers for performance growth: business expansion, cost control, and non-recurring gains/losses impact [Primary Factors for Performance Growth](index=1&type=section&id=Item%203.%20Explanation%20of%20Performance%20Change_1.%20Primary%20Reasons%20for%20Performance%20Growth) Growth driven by expanded gas business, capacity release, increased production/sales, boosting revenue and gross margin - Expanded gas business scale, released capacity, and increased production and sales volumes are driving **revenue growth**[5](index=5&type=chunk) - Reduced costs and improved gross margin positively impact **performance growth**[6](index=6&type=chunk) [Impact of Non-recurring Gains and Losses](index=2&type=section&id=Item%203.%20Explanation%20of%20Performance%20Change_2.%20Impact%20of%20Non-recurring%20Gains%20and%20Losses) Non-recurring gains and losses are projected to impact net profit by approximately **CNY 8.70 million** - The estimated impact of non-recurring gains and losses on net profit is approximately **CNY 8.70 million**[6](index=6&type=chunk) Important Notes and Disclosures Highlights preliminary nature of forecast, advises investor caution, and lists available reference documents [Communication with Accounting Firm](index=1&type=section&id=Item%202.%20Communication%20with%20Accounting%20Firm) Forecast data is a preliminary calculation by finance department, **unaudited** by an accounting firm - The performance forecast data is a preliminary calculation by the company's finance department and has **not been audited** by an accounting firm[4](index=4&type=chunk) [Other Disclosures](index=2&type=section&id=Item%204.%20Other%20Related%20Disclosures) Unaudited forecast data is subject to H1 2025 report; investors should exercise caution due to uncertainties and risks - The performance forecast data is unaudited, and final figures will be based on the **2025 semi-annual report**[7](index=7&type=chunk) - The performance forecast data contains uncertainties, and investors should exercise **prudent decision-making** and be aware of **investment risks**[7](index=7&type=chunk) [Reference Documents](index=2&type=section&id=Item%205.%20Reference%20Documents) Board of directors issued a statement on H1 2025 performance forecast, available as a reference document - The reference document is the board of directors' explanation regarding the **H1 2025 performance forecast**[8](index=8&type=chunk)

Core Viewpoint - Qiaoyuan Co., Ltd. has obtained a production license for medical liquid oxygen, which is expected to enhance its competitiveness in the pharmaceutical sector and positively impact its future operations [1] Group 1: Company Developments - Qiaoyuan's wholly-owned subsidiary, Qiaoyuan (Jintang) Gas Co., Ltd., has recently received the approval from the Sichuan Provincial Drug Administration for the renewal of its "Drug Production License" [1] - The production scope has been changed to include medical gases, specifically liquid oxygen, after passing the GMP compliance inspection [1] - This change is anticipated to expand the company's production and sales of medical oxygen products [1] Group 2: Industry Impact - The approval is expected to enhance the company's competitiveness in the pharmaceutical field [1] - The positive implications for the company's future operations are highlighted, indicating a strategic move within the medical gas industry [1]